Sargramostim (rhu GM-CSF) and Immune Checkpoint Inhibitors : Combinatorial Therapeutic Studies in Metastatic Melanoma(Post)
Metastatic melanoma presents significant treatment challenges, but advancements in immunotherapy, particularly the combination of Sargramostim (rhu GM-CSF) and immune checkpoint inhibitors, offer pr ...
Exploring Biosimilar Reference Antibodies(Page)Exploring Biosimilar Reference Antibodies for Advanced Research and Biotech Applications Explore how Oursmab biosimilar antibodies are transforming biotech research. Learn about their uses in prot ...
Product results
Product results
- Product
- Qty in Cart
- Quantity
- Price
- Subtotal
-
zł2,080.80 -
SHIKARI Q-PEM (Pembrolizumab) ELISA | 30137260
zł9,326.88SHIKARI Q-PEM (Pembrolizumab) ELISA | 30137260 | IBL International Application: ELISA Category Type: Immunology181-30137260zł9,326.88 -
SHIKARI S-ATP (Anti-Pembrolizumab Ab) ELISA | 30137262
zł9,326.88SHIKARI S-ATP (Anti-Pembrolizumab Ab) ELISA | 30137262 | IBL International Application: ELISA Category Type: Immunology181-30137262zł9,326.88 -
pHR_Gal4UAS_Pembrolizumab_heavychain_T2A_ Pembrolizumab_lightcha
zł1,627.92Order pHR_Gal4UAS_Pembrolizumab_heavychain_T2A_ Pembrolizumab_lightcha from Nova Lifetech / Life Science Market by email to eu@genprice.comPVT11019zł1,627.92